PURPOSE: Using positron emission tomography in isoflurane-anaesthetised cat, we recently demonstrated that the effect of D-amphetamine (AMPH) was greater on the binding potential (BP(ND)) of the agonist dopamine D2/D3 radiotracer (+)-4-[(11)C]propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1, 4]oxazin-9-ol ([(11)C]-(+)-PHNO) than on that of the antagonist [(11)C]-raclopride, a finding that we were unable to replicate in conscious rat. Herein we tested whether isoflurane differentially affects the AMPH sensitivity of [(11)C]-(+)-PHNO and [(3)H]-raclopride. PROCEDURES: Conscious or isoflurane-anaesthetised rats pretreated intravenously (i.v.) with saline or 4 mg/kg AMPH were co-injected i.v. with [(11)C]-(+)-PHNO/[(3)H]-raclopride or [(3)H]-(+)-PHNO/[(11)C]-(-)-N-propyl-norapomorphine ([(11)C]-(-)-NPA) and euthanised 2, 10, 20, 30, 40 or 60 min following [(11)C]-(+)-PHNO/[(3)H]-raclopride or 60 min following [(3)H]-(+)-PHNO/[(11)C]-(-)-NPA. Striatal binding at 60 min, estimated by the specific binding ratio (SBR) and the binding potential with respect to non-displaceable binding (BP(ND)) for pseudodynamic data, was calculated using the simplified reference tissue model. RESULTS: Isoflurane increased [(11)C]-(+)-PHNO, [(3)H]-(+)-PHNO and [(11)C]-(-)-NPA SBR (mean ± SD) by 80 ± 30%, 170 ± 50% and 120 ± 40%, and doubled the effect of AMPH on the SBR of these radiotracers to -61 ± 9%, -69 ± 12% and -60 ± 12%, respectively. Neither effect was seen for [(3)H]-raclopride SBR. Similar results were observed for [(11)C]-(+)-PHNO and [(3)H]-raclopride BP(ND). CONCLUSIONS: Isoflurane differentially increases the binding and AMPH sensitivity of [(11)C]-(+)-PHNO and [(11)C]-(-)-NPA relative to [(3)H]-raclopride, suggesting that agonist radiotracers will prove no more effective for imaging dopaminergic activity in human than antagonist radiotracers.
PURPOSE: Using positron emission tomography in isoflurane-anaesthetised cat, we recently demonstrated that the effect of D-amphetamine (AMPH) was greater on the binding potential (BP(ND)) of the agonist dopamine D2/D3 radiotracer (+)-4-[(11)C]propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1, 4]oxazin-9-ol ([(11)C]-(+)-PHNO) than on that of the antagonist [(11)C]-raclopride, a finding that we were unable to replicate in conscious rat. Herein we tested whether isoflurane differentially affects the AMPH sensitivity of [(11)C]-(+)-PHNO and [(3)H]-raclopride. PROCEDURES: Conscious or isoflurane-anaesthetised rats pretreated intravenously (i.v.) with saline or 4 mg/kg AMPH were co-injected i.v. with [(11)C]-(+)-PHNO/[(3)H]-raclopride or [(3)H]-(+)-PHNO/[(11)C]-(-)-N-propyl-norapomorphine ([(11)C]-(-)-NPA) and euthanised 2, 10, 20, 30, 40 or 60 min following [(11)C]-(+)-PHNO/[(3)H]-raclopride or 60 min following [(3)H]-(+)-PHNO/[(11)C]-(-)-NPA. Striatal binding at 60 min, estimated by the specific binding ratio (SBR) and the binding potential with respect to non-displaceable binding (BP(ND)) for pseudodynamic data, was calculated using the simplified reference tissue model. RESULTS:Isoflurane increased [(11)C]-(+)-PHNO, [(3)H]-(+)-PHNO and [(11)C]-(-)-NPA SBR (mean ± SD) by 80 ± 30%, 170 ± 50% and 120 ± 40%, and doubled the effect of AMPH on the SBR of these radiotracers to -61 ± 9%, -69 ± 12% and -60 ± 12%, respectively. Neither effect was seen for [(3)H]-raclopride SBR. Similar results were observed for [(11)C]-(+)-PHNO and [(3)H]-raclopride BP(ND). CONCLUSIONS:Isoflurane differentially increases the binding and AMPH sensitivity of [(11)C]-(+)-PHNO and [(11)C]-(-)-NPA relative to [(3)H]-raclopride, suggesting that agonist radiotracers will prove no more effective for imaging dopaminergic activity in human than antagonist radiotracers.
Authors: Nicholas Seneca; Sjoerd J Finnema; Lars Farde; Balázs Gulyás; Håkan V Wikström; Christer Halldin; Robert B Innis Journal: Synapse Date: 2006-04 Impact factor: 2.562
Authors: Nathalie Ginovart; Laurent Galineau; Matthaeus Willeit; Romina Mizrahi; Peter M Bloomfield; Philip Seeman; Sylvain Houle; Shitij Kapur; Alan A Wilson Journal: J Neurochem Date: 2006-04-05 Impact factor: 5.372
Authors: Paul Cumming; Dean F Wong; Nicholas Gillings; John Hilton; Ursula Scheffel; Albert Gjedde Journal: J Cereb Blood Flow Metab Date: 2002-05 Impact factor: 6.200
Authors: Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2012-12-09 Impact factor: 3.000
Authors: Paul Shotbolt; Andri C Tziortzi; Graham E Searle; Alessandro Colasanti; Jasper van der Aart; Sergio Abanades; Christophe Plisson; Sam R Miller; Mickael Huiban; John D Beaver; Roger N Gunn; Marc Laruelle; Eugenii A Rabiner Journal: J Cereb Blood Flow Metab Date: 2011-08-31 Impact factor: 6.200
Authors: Fernando Caravaggio; Shinichiro Nakajima; Carol Borlido; Gary Remington; Philip Gerretsen; Alan Wilson; Sylvain Houle; Mahesh Menon; David Mamo; Ariel Graff-Guerrero Journal: Neuropsychopharmacology Date: 2014-05-30 Impact factor: 7.853
Authors: Vladimir Shalgunov; Jan-Peter van Wieringen; Henk M Janssen; P Michel Fransen; Rudi A J O Dierckx; Martin C Michel; Jan Booij; Philip H Elsinga Journal: EJNMMI Res Date: 2015-07-25 Impact factor: 3.138
Authors: Kristoffer Sahlholm; Jurgen W A Sijbesma; Bram Maas; Chantal Kwizera; Daniel Marcellino; Nisha K Ramakrishnan; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde Journal: Psychopharmacology (Berl) Date: 2015-07-11 Impact factor: 4.530